Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease
Recruiting · NCT07001150 · Interventional (participants receive a specific treatment) · Lead sponsor: Tanta University
View the official record on ClinicalTrials.gov →Interventions studied
Silymarinlevodopa-carbidopa
What this trial is about
Parkinson's disease (PD) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein protein aggregates. Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, will be studied for its neuroprotective effects in PD.
Who can take part
Age range
45 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Age between 45 and 65 years old
- Both sexes
- Patients with Parkinson's disease on dopamine replacement therapy
- Modified Hoehn and Yahr stage, MHY 1-4 (29)
Exclusion criteria
- Subjects \< 18 years of age
- Pregnant or breastfeeding women
- Suspected hypersensitivity to silymarin or multivitamins
- Advanced liver disease (e.g., ascites, bleeding esophageal varices, and hepatic encephalopathy)
- Subjects with morbid obesity, i.e., a Body Mass Index (BMI) \> 40
- Subjects with severe illness, e.g., multisystem failure, cancer, or poorly controlled diabetes, i.e., known diabetic with Hemoglobin A1C (HbA1C)\>7%
- Current use of Silymarin or recent use within the past two weeks.
- Other conditions, which, in the opinion of the investigators, make the patient unsuitable for enrollment.
Where it is running
1 location listed.
- Tanta Hospital for Mental Health - Tanta, Tanta, Qism 2, Egypt